MARK CANNING: Open Payments
NPI 1366548141 · VAUXHALL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$289 in 16 payments from 8 companies in 2025. Trend: 2023 $88 · 2024 $129 · 2025 $289
Food & beverage: $289
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 4 | $74 |
| Alkermes, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| ABBVIE INC. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: INVEGA SUSTENNA, ARISTADA, UZEDY, ABILIFY ASIMTUFII, REXULTI, INGREZZA, VRAYLAR, HETLIOZ.
Industry payments across NJ — which companies pay providers there.
